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Introduction
Hearing loss (HL) or deafness is the most frequent con-
genital sensory impairment in humans, which is a very het-
erogeneous trait. Based on the World Health Organization’s 
(WHO) data, in 2020 around 466 million people worldwide 
had disabling hearing loss, and 34 million of these people 
were children [1]. The incidence of severe to profound deaf-
ness in the first two decades of life is about 1 in 650 new-
borns. 
Over 150 associated loci and about 80 different protein-
coding genes are involved in the perception of sound, up 
to 1% of these causative human genes have been mapped. 
Mutations in these genes can lead to similar clinical mani-
festations of hearing impairment. Non-syndromic HL ac-
counts for up to 70% of genetic deafness, which is almost 
exclusively monogenic [2]. 
More than half of cases of congenital autosomal recessive 
non-syndromic HL resulted from mutations in the DFNB1 
locus. Prelingual non-progressive sensorineural forms of 
deafness are expressed as moderate to profound [3]. 
The DFNB1 (OMIM 220290) locus on chromosome 13 
(13q11-q12) contains two genes, GJB2 (OMIM 121011) and 
GJB6 (OMIM 604418) [4]. Encoding connexin 26 (Cx26) 
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Abstract
Background: Guanine deletion 35delG in GJB2 exon 2 is the pathogenic mutation responsible for up to 70% of cases of congenital non-syndromic 
sensorineural hearing loss (NSHL) among Europeans. The early molecular diagnostic of hearing loss nature has become important while considering 
the cochlear implants. The purpose of this study was to establish the frequency of 35delG deletion in GJB2 gene among patients with severe NSHL and 
its prevalence among Moldovan residents with normal hearing.
Material and methods: 40 patients with congenital bilateral profound NSHL and 300 individuals with normal hearing were examined for deletion 35delG, 
by using Custom TaqMan SNP genotyping Assay.
Results: 12 (30%) patients with homozygous genotype for 35delG mutation were identified, whereas 8 patients (20%) were heterozygous. The study 
reported 4 (1.33%) carriers of 35delG mutation among 300 Moldovan individuals with normal hearing.
Conclusions: The present study results suggest a need for including the 35delG molecular testing into the national program of neonatal screening of 
hearing loss. Considerations on the genetic carrier testing should be made in genetic counseling and family planning.
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and connexin 30 (Cx30), respectively are members of in-
tracellular gap junction β proteins family. In the inner ear, 
the six monomers of Cx26 or Cx30 oligomerize to form as 
homo- or heteromeric connexons, which are involved in the 
recycling of ions K+ between hair cells and endolymph [5, 
6]. This is believed to play a crucial role in efficient genera-
tion of action potentials in mechanosensory transduction 
of sound. 
The literature review demonstrated that more than 100 
pathogenic mutations in the GJB2 gene have been identi-
fied with a significant contribution of the frameshift and 
nonsense mutations [7, 8]. The frequency of the individual 
mutations associated with HL varies within ethnic groups 
[9]. In Caucasians, the most frequent mutation is 35delG 
(rs80338939) a point deletion of one of six guanines at the 
codon position 30-35 of the second exon. This deletion leads 
to shifted reading frame, creation of stop codon, and prema-
ture termination of the protein Cx26 synthesis [10, 11].
This study was aimed to establish the carrier frequency 
of 35delG deletion in GJB2 gene among patients with severe 
NSHL and among Moldovan population with normal hea-
ring.  
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Material and methods 
40 children with prelingual non-syndromic HL from the 
Republic of Moldova and Romania and 300 unrelated par-
ticipants with normal hearing were included in the study. 
Written informed consent was signed by all the minors’ par-
ents and by healthy participants. 
A total 40 hearing impaired children (aged 1-14 years) 
underwent audiological analysis. The degree of their hear-
ing loss was evaluated as severe (71-90 dB) to profound 
(>90dB), according to the HL Classification from WHO.
All examined volunteers with normal hearing were aged 
between 18-29 years. Venous blood samples were taken 
from all participants.  
Genomic DNA isolation from 100 µL of peripheral blood 
was performed with proteinase K and spin column puri-
fication protocol (#K0722, ThermoFisher Scientific). The 
purity and concentration of DNA samples were detected 
using a NanoDrop 2000c spectrophotometer (ThermoFisher 
Scientific). The average DNA concentration of each sample 
was adjusted to 2 ng/µL.
The targeted search for the 35delG mutation was de-
tected using a Custom TaqMan SNP Genotyping Assay Kit 
(#4351379, ThermoFisher Scientific) [12]. The primers and 
MBG probes for allelic discrimination assay were designed 
using software Primer3 web version [13]. 
The molecular-genetic analysis was performed in a to-
tal reaction volume of 5 µL on 384-well plates. All samples 
analysis was performed on the QuantStudio 6 flex device 
(Applied Biosystems, ThermoFisher Scientific), according 
to manufacturer’s protocol. The allelic discrimination data 
were analyzed using a TaqMan Genotyper Software applica-
tion (v.1.3.1., Applied Biosystems, ThermoFisher Scientific). 
The successful genotyping call rate was <96%, the undeter-
mined samples were automatically eliminated from allelic 
discrimination analysis. 
Statistical analysis was performed using the Statistica 
v.6.0 software.
Results
The molecular screening for the pathological allele in 
GJB2 gene among the group of children revealed 12 (30%) 
patients with homozygous genotype for 35delG mutation 
and 8 patients (20%) with heterozygous form. Genotyping 
among 300 individuals with normal hearing identified 4 
subjects with carrier rate of 1.33%. The distribution of allele 
frequencies of the rs80338939 samples analyzed is shown in 
fig. 1.
Discussion
The major pathogenic mutation is point deletion 35delG 
(rs80338939), which accounts for about 70% of recessive 
mutations of GJB2 associated with NSHL in populations of 
European origin, with a carrier frequency of 2-4% [9-11]. 
Other ethnic groups may have additional or different spe-
cific mutations, such as 235delC (rs80338943) in Japanese 
and Koreans, 167delT (rs80338942) among Ashkenazi Jews, 
R143W (rs80338948) in Africans [14-16]. W24X mutation 
has a high frequency in Indian and Roma populations [17]. 
Almost half of the recessive mutations are frameshift of 
nonsense type. They have no specific localization and can 
affect all domains of Cx26 protein [3, 7]. 
These study findings showed that the prevalence of 
35delG mutation in GJB2 gene among volunteers with nor-
mal hearing was around 1.33% (4/300). This is in concor-
dance with similar data obtained for other European po-
pulations. According to our data, the 35delG deletion was 
identified in the homo- or heterozygous state in 50% of the 
patients. 
On the other hand, 20% of samples tested were found to 
have only one mutant allele, 50% of patients had non-carrier 
rate of 35delG mutation. These results could be explained by 
the fact that other recessive mutations were present in GJB2 
gene in homozygous or compound heterozygous form. It 
is known that, the NSHL may also develop in compound 
heterozygous form of the GJB2 mutations with the second 
mutation in GJB6 (Cx30) gene in the DFNB1 locus [9]. In 
the case of compound heterozygote of two genes, the ex-
pression of these genes is probably affected which is not due 
to digenic inheritance, as previously assumed [2, 8].
Therefore, it is clinically important to explore other re-
cessive disease-causing mutations in GJB2 gene and to es-
tablish a relationship between genotype and phenotype cor-
relation [18].
Due to high frequency of worldwide hearing impair-
ment and its public health impact, early identification and 
stratification of patients with HL becomes an important 
Fig. 1. Allelic Discrimination Plot showing  
35delg/rs80338939 Assay
Notes: Representative plot showing performance of allelic Discrimination 
of 35delG/rs80338939 SNP. 
Separation between the signals derived from allele 1 (VIC) and allele 2 
(FAM). The red cluster represents homozygous mutants containing copies 
of the 35delG mutant allele. The green cluster includes individuals having 
one normal and mutant allele (heterozygous). The blue cluster represents 
samples homozygous with normal sequence for both alleles.
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issue. In addition to main directions, research should also 
focus on the optimization of methods for molecular diag-
nostics, gene expressions in choosing gene therapy of he-
reditary pathologies, as well as on prediction of the correct 
treatment strategy and the estimation of risk of disease re-
currence in families.
Conclusions
Our study results support the position that 35delG mu-
tations are a cause in the etiology of non-syndromic hearing 
loss in other European populations. 
In addition, genetic defects that underline deafness 
could become a good foundation for gene therapy develop-
ment, treatment strategy, and treatment success. It should 
be used as a tool in molecular testing to detect genetic origin 
of deafness in population of Moldova. Our findings suggest 
including the 35delG testing into the national program of 
neonatal hearing loss screening. Taking clinical and social 
impact of NSHL into consideration it is advisable to intro-
duce carrier detection testing in genetic counseling and 
family planning.
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